MedTrace Logo

Safety and Efficacy Study of Artesunate and Mefloquin in Children With Uncomplicated Malaria

NCT00978172 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 220

Last updated 2009-09-16

No results posted yet for this study

Summary

The present study aims to investigate and to assess possible neurological and neuropsychiatric events in young children in west Africa with uncomplicated P. falciparum malaria after a 3-day treatment of Artequin Paediatric under "real life conditions."

Conditions

Interventions

DRUG

artesunate and mefloquine

artesunate (50 mg/day) and mefloquine (125 mg/day) fixed dose formulation (stick pack) once daily for 3 consecutive days, orally

Sponsors & Collaborators

  • Centre Mère et Enfant de la Fondation Chantal Biya

    collaborator OTHER

  • Mepha Ltd.

    lead INDUSTRY

Principal Investigators

  • Felix Tietche, Prof · Faculty of Medicine and Biomedical Sciences University of Yaounde (Cameroon)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Completion
2009-03-31

Countries

  • Cameroon

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00978172 on ClinicalTrials.gov